(Q34978317)

5 August 2017

1 reference

title

Treatment of fludarabine-refractory chronic lymphocytic leukemia (English)

1 reference

5 August 2017

0 references

1 reference

2

Michael J Keating

1 reference

PubMed ID

19402170

Apostolia Maria Tsimberidou

5 August 2017

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

PubMed ID

19402170

5 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

5 August 2017

1 reference

5 August 2017

115

1 reference

5 August 2017

13

1 reference

5 August 2017

2824-2836

1 reference

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

5 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Detection of human leukaemia associated antigens in leukaemic serum and normal embryos

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

The potential role of Nutlins in the treatment of B-chronic lymphocytic leukemia (B-CLL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24329

7 January 2021

Identifiers

DOI

10.1002/CNCR.24329

1 reference

5 August 2017

1 reference

PubMed ID

19402170